Ram Isanaka-FOUNDED ISSAR PHARMACEUTICALS-to develop new peptide molecules addressing the unmet healthcare needs.
ISSAR conducted the FIRST HUMAN CLINICAL TRIALS FOR MELGAIN (phase 1). ISSAR was the first and the only company to have conducted phase 1 clinical trial in India since independence.
ISSAR commercialised the first ever peptide solution for Vitiligo.
MELGAIN was launched into the market for the treatment of VITILIGO.
ISSAR received NOC to conduct Phase 1 and Phase 2 trials from DCGI.
ISSAR pharmaceuticals established their state-of-the-art, FDA-compliant, 62000 sq ft., manufacturing facility at Genome Valley, Hyderabad, India.
Successfully completed Phase 1 clinical trial for cancers (solid tumors).
ISSAR successfully completed phase III clinical trials for BURN WOUNDS treatment.
ISSAR got permission to manufacture finished formulation of a new drug for the treatment of burn wounds
ISSAR got permission to manufacture and market burn wound product.